Ara-290 16mg

Ara-290, also known as Cibinetide, is an 11-amino-acid synthetic peptide derived from the helix-B region of erythropoietin (EPO). It was designed to replicate EPO’s tissue-protective and inflammatory signalling properties without stimulating erythropoiesis (red blood cell production).

Ara-290 selectively binds the innate repair receptor (IRR), a heterodimer of the EPO receptor and CD131 (beta common receptor). This receptor is expressed on immune cells, endothelial cells, and neurons, and is distinct from the classical EPO receptor responsible for haematopoietic signalling.

Preclinical and early clinical research has investigated Ara-290 in models of neuropathic pain, diabetic neuropathy, retinal ischaemia, and immune modulation. Studies have reported anti-apoptotic and inflammatory pathway modulation activity, with proposed mechanisms including suppression of pro-inflammatory cytokines (IL-6, TNF-alpha) and preservation of endothelial barrier function.

A Phase II clinical trial (NCT01445379) evaluated Ara-290 in patients with sarcoidosis-associated small fibre neuropathy, representing one of the most advanced human studies of an IRR-targeting peptide.

Note: Ara-290 may exhibit unusual reconstitution behaviour in bacteriostatic water due to self-association during hydration. Phosphate Buffered Saline (PBS) at pH 7.4 is recommended as the reconstitution solvent for optimal solubility.

For In-Vitro Research Use Only. Not for human consumption, veterinary use, or clinical application. No dosing guidance is provided or implied.